Sylics (part of InnoSer)

Sylics offers innovative research solutions for preclinical neuroscience.

We specialize in developing and employing mouse models and behavioural tests to evaluate compound effects on, and disease mechanisms of, neurological and psychiatric diseases, with a strong focus on Alzheimer’s disease, Parkinson’s disease and Schizophrenia.

Sylics is a research intensive company that develops research solutions in preclinical neuroscience. Sylics CRO runs preclinical neuroscience studies for national and international biotech, food & pharma partners in a facility in Amsterdam. These studies focus on assessing the effect of novel therapeutic strategies to treat brain diseases such as Alzheimer’s disease and Schizophrenia.
Sylics Bioinformatics provides data analyses services to customers worldwide, using its proprietary cloud-based data analysis platform AHCODA™. This automated screening platform increases efficiency and sensitivity to detect behavioural deficits in mouse models.

Over the last 10 years, we successfully characterized dozens of novel mouse models, and determined compound efficacy and side-effects in numerous projects for academia, biotech, and food industry clients.

InnoSer expands its preclinical neuroscience expertise with the acquisition of Sylics
 
This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis as well as key rare genetic disease models such as infantile epileptic encephalopathy, fragile X syndrome and vanishing white matter.

Leiden and Bilthoven, the Netherlands, January 12, 2023 – InnoSer, an innovator in preclinical research services with operations in Diepenbeek, Belgium and Leiden, The Netherlands, is pleased to announce that it has entered into a final agreement to acquire Sylics, a contract research organisation (CRO) specialized in efficacy testing using rodent in vivo models of neurological and psychiatric diseases.

Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical drug development from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well characterized in vitro and in vivo disease models in addition to general drug development services, allowing to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds.